HIGHBuilt-inPipeline
COMP360 psilocybin treatment (sole clinical program)
“10-K Item 1: 'We are currently focusing our efforts on progressing our Phase 3 clinical program in TRD and our Phase 2b/3 clinical trial in PTSD.'”
CMPS · Concentration risk · 10-K extracted
COMPASS Pathways Plc - American (CMPS) concentration risks
Updated
The most significant concentration COMPASS Pathways Plc - American discloses is COMP360 psilocybin treatment (sole clinical program), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: COMPASS Pathways Plc - American’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06COMPASS Pathways' concentration risk is essentially total and pipeline-driven: the company is focusing its efforts on a single clinical program, COMP360 psilocybin treatment, currently progressing through a Phase 3 trial in treatment-resistant depression and a Phase 2b/3 trial in PTSD, a high, structural concentration. With no other named product candidate disclosed in these sources, the entire investment case rests on the outcome of COMP360's trials across its two indications. This is the defining characteristic of a single-asset clinical-stage company: there is no secondary program to offset a negative trial readout in either TRD or PTSD, and a delay or failure in either indication would directly affect the company's near-term trajectory since both indications share the same underlying compound. Because the disclosed exposure is structural rather than a dependency on a specific counterparty or customer, the risk is best understood as binary clinical and regulatory risk concentrated in one compound, rather than a relationship that could be renegotiated or replaced.
For the engine’s reasoning on CMPS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Care Facilities
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACHC | Acadia Healthcare Company, Inc. | 1 | 1 | 0 | 2 |
| CMPS● | COMPASS Pathways Plc - American | 1 | 0 | 0 | 1 |
| ADUS | Addus HomeCare Corporation | 0 | 2 | 4 | 6 |
| ARDT | Ardent Health, Inc. | 0 | 2 | 0 | 2 |
| AMN | AMN Healthcare Services Inc | 0 | 0 | 1 | 1 |
| AGL | agilon health, inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.